{
    "2021-12-08": [
        [
            {
                "time": "",
                "original_text": "复星医药参股成立企业管理合伙企业，注册资本1000万元",
                "features": {
                    "keywords": [
                        "复星医药",
                        "参股",
                        "企业管理",
                        "合伙企业",
                        "注册资本"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "企业管理"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "2021-12-09",
                "original_text": "企业服务领域投资日报（12月9日）：星创健康科技被复星医药并购",
                "features": {
                    "keywords": [
                        "星创健康科技",
                        "并购",
                        "复星医药"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "健康科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "复星医药持有亚能生物技术股份降至20%",
                "features": {
                    "keywords": [
                        "复星医药",
                        "亚能生物",
                        "持股比例",
                        "下降"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "复星医药：复星诊断提供的三靶标高灵敏核酸检测方案，可覆盖新冠病毒变异株的检测",
                "features": {
                    "keywords": [
                        "复星医药",
                        "核酸检测",
                        "新冠病毒",
                        "变异株"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "诊断技术"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}